Class III status is the key signal when determining whether a device needs Premarket Approval. In the United States, PMA is the FDA pathway for evaluating the safety and effectiveness of Class III medical devices, and the PMA medical device manufacturing requirements support the evidence and controls behind that review. The U.S. Food and Drug Administration has 180 days to review and decide on a PMA application.

It’s reasonable to treat this as a manufacturing question: the submission must describe how the device is made and show that production controls support the evidence for safety and effectiveness. But the first decision is the regulatory pathway. A device’s classification, intended use, risk profile, and relationship to legally marketed devices all help determine whether PMA is appropriate.

This article explains what Premarket Approval covers, which devices may require it, and how a traditional PMA brings clinical, nonclinical, manufacturing, and quality information together in one application. It also explains how administrative completeness and manufacturing controls factor into preparation, helping you assess the pathway before committing resources to a submission.

What is Premarket Approval?

Premarket Approval (PMA) is the FDA pathway for evaluating the safety and effectiveness of Class III medical devices. Reviewers assess scientific evidence alongside the device’s design, production controls, and proposed use.

Safety and Effectiveness Review

FDA evaluates whether evidence supports a device’s safety and effectiveness for its intended use. Evidence may include clinical investigation results, nonclinical testing, and an explanation of how risks compare with expected benefits. Applicants should connect study outcomes to the final device design: changes to materials, software, or manufacturing can affect how reviewers interpret the evidence.

A PMA application must support its conclusions with organized, consistent information. Reviewers assess the scientific rationale, study methods, results, labeling, and manufacturing details as parts of a single safety case. If clinical evidence concerns one device configuration but production records describe another, the mismatch can prompt questions. The rationale for each design choice and its effect on performance should be traceable throughout the submission.

Review includes both filing and substantive evaluation. According to the U.S. Food and Drug Administration, the FDA has 180 days to review and decide on a PMA application. If reviewers request additional information, the response must address the identified issues with relevant evidence, not simply restate earlier conclusions. After receiving additional information, the FDA may take an additional 180 days before deciding or requesting more information.

Applicants can work with FDA reviewers by responding clearly to questions, organizing supporting data, and explaining any changes made during review. The FDA offers Day-100 meetings for PMA applicants during application review. A focused discussion can clarify outstanding issues, while a response matrix can connect each FDA question to its answer, evidence, and affected application section.

Some applications are reviewed by the FDA’s Center for Biologics Evaluation and Research (CBER). Special requirements apply to PMA applications for devices regulated by CBER, so the responsible center affects preparation and review. Products combining device and biologic functions may also involve center-specific considerations. Identify the product’s regulatory context and present evidence accordingly.

Manufacturing Site Evaluation and Inspection Risks

FDA evaluates manufacturing sites to determine whether production controls support the device described in the PMA. A facility inspection is typically required before approval to assess compliance with applicable quality requirements. Inspectors may examine records, process controls, validation evidence, and how the site handles production deviations. Unresolved gaps can undermine confidence that commercial units will match the tested device.

Common inspection concerns include incomplete records, unvalidated production processes, inconsistent procedures, and ineffective corrective action. For example, inadequate validation evidence for a sterilization process creates a gap between the stated process and its demonstrated control. Findings may prompt requests for corrective evidence, delay review, or affect the approval decision. PMA medical device manufacturing requirements therefore extend beyond the application narrative to production-site records and controls.

Administrative completeness and application quality control

A complete PMA application connects the device’s evidence, manufacturing information, and administrative records. Class III devices generally require PMA, and the submission must demonstrate that the device is appropriate for its intended use and can be produced consistently.

Classification shapes the starting point. Class I devices are subject to general controls; Class II devices are subject to general and Special Controls; Class III devices are subject to general controls and Premarket Approval. A PMA applicant should verify the device’s classification and pathway before assembling records. A device with a suitable predicate may use 510(k), which demonstrates substantial equivalence; a novel, lower-risk device may qualify for De Novo.

Administrative checks help prevent omissions from obscuring the scientific and manufacturing case. A quality-control review can compare the application’s table of contents against its exhibits, confirm consistent device names and model identifiers, and check that every referenced report is present. Required items include Form FDA-3674, financial certification or disclosure statements under 21 CFR 54, and an environmental assessment under 21 CFR 25, subject to applicable exceptions. According to the U.S. Food and Drug Administration, the FDA notifies a PMA applicant within 45 days whether the application has been filed.

Pending applications also require controlled updates. Applicants must provide relevant new safety and effectiveness information and submit update reports three months after the filing date. Assess changes in clinical findings, design, or manufacturing information for their effects on other sections, keeping the submission internally consistent.

For PMA device manufacturers, the Quality Management System Regulation (QMSR) replaced the Quality System Regulation on February 2, 2026. The FDA quality system requirements are codified under 21 CFR Part 820, and ISO 13485 is a quality management standard for medical device manufacturers. Contract manufacturers and foreign facilities should be represented accurately in manufacturing descriptions, process records, and validation evidence; the submission must make clear how production controls relate to the finished device.

Manufacturing requirements differ by pathway because PMA requires an application supporting safety and effectiveness, while 510(k) focuses on substantial equivalence and De Novo applies to eligible novel devices. Quality controls remain relevant to production in each pathway. FDA charges a fee to review PMA applications; manufacturing compliance costs depend on the work needed for process validation, testing, documentation, and facility controls.

For complex device assembly, organize process records and validation evidence alongside the application’s manufacturing description. A focused discussion about assembly documentation can help align production records with the device configuration described in the submission.

Traditional PMA submissions

A traditional PMA is submitted as one complete application package, typically after clinical testing is complete. Organize it so FDA reviewers can trace each conclusion to the supporting evidence and manufacturing information. PMA medical device manufacturing requirements should be reflected consistently throughout, from device specifications to production records.

PMA Evidence and Submission Requirements

A traditional PMA brings together clinical results, nonclinical testing, device information, and manufacturing details. This evidence matters because reviewers assess whether it supports the device’s safety and effectiveness for its intended use. Under 21 CFR part 814.20, the application includes required content; the table of contents should guide reviewers to each section and exhibit.

Nonclinical laboratory studies must include a statement of compliance with 21 CFR 58, Good Laboratory Practice for Nonclinical Laboratory Studies, or briefly explain noncompliance. Clinical materials should correspond to the device and investigation described in the application. PMA submissions must include copies of individual subject report forms for each clinical-investigation subject who died or did not complete the investigation.

Manufacturing content includes procedures, sterilization validation, design specifications, testing results, labeling, and risk analyses. If required information is omitted, the applicant must identify and justify each omission in a separate section listed in the table of contents. Where complete manufacturing information is temporarily unavailable, the omission may be justified under 21 CFR 814.20(d).

FDA accepts PMA submissions in an electronic format called eCopy, provided on a CD, DVD, or flash drive. The submission must also include a signed paper copy of the cover letter. Treat the cover letter and coversheets as controlled components: keep device and applicant details consistent, identify the submission clearly, and ensure the electronic files match the package contents.

Design, Process, and Supplier Controls

Design, process, and supplier controls connect the tested device to the device described for manufacturing. Evidence is less persuasive if production uses different specifications, materials, or validated processes. For a traditional PMA, PMA medical device manufacturing requirements call for traceable design records, documented process validation, and supplier controls that support critical component specifications.

For example, sterilization validation should match the stated process, product configuration, and packaging. Supplier records should show how component requirements are communicated and how changes are assessed. These controls help prevent discrepancies between clinical evidence, manufacturing procedures, and finished-device specifications.

Communication with FDA before filing can help applicants frame questions about study plans, test methods, and submission organization. Prepare a concise agenda, identify the exact device configuration, and present the evidence available. Record FDA feedback and link resulting decisions to the application’s clinical, nonclinical, or manufacturing sections.

Before finalizing the submission, conduct a cross-functional review. Regulatory, clinical, engineering, and manufacturing reviewers can check that names, specifications, test reports, and process descriptions agree throughout the package. A discrepancy log helps assign corrections and confirm that revised files appear in the final eCopy.

Determining whether a medical device requires PMA

The regulatory pathway depends on a device’s classification, intended use, risk, and relationship to legally marketed devices. Compare these factors before planning testing, laboratory work, and submission activities.

Understanding Premarket Approval

Premarket Approval is the FDA pathway for evaluating the safety and effectiveness of Class III devices. Determining whether PMA applies matters because the pathway defines the evidence and manufacturing information needed before marketing.

Class III devices generally require a PMA application under section 515 of the FD&C Act. Their risk profile and intended use shape the scientific evidence needed to support the application. A regulatory assessment should therefore begin with the device’s intended purpose and classification, rather than assuming that similar technology always follows the same pathway.

FDA classifies devices as Class I, Class II, or Class III, with different controls for each class. Class I devices are subject to general controls, Class II devices to general and Special Controls, and Class III devices to general controls and Premarket Approval. Classification is a starting point, not a substitute for checking the applicable device regulation and submission type.

Identifying Devices That Require PMA

A device generally requires PMA when FDA classifies it as Class III and no applicable alternative pathway or exception applies. Choosing the wrong pathway can misalign the submission’s evidence with the FDA review process.

Use the device’s intended use and technological characteristics to assess its classification and regulatory history. A device substantially equivalent to a legally marketed predicate is generally submitted through 510(k), which is a clearance mechanism, not an approval process. Class II devices generally require 510(k); a novel device with a lower risk profile may qualify for De Novo instead.

Some Class III preamendment devices may require a Class III 510(k) rather than PMA. This historical distinction relates to devices marketed before the 1976 Medical Device Amendments. Check the device’s classification and submission type, then assess whether the relevant listing identifies a PMA or 510(k) route.

Apply these decision points to the specific device:

• Classification: Is the device Class III, or does FDA place it in another class?
• Predicate: Is there a legally marketed device supporting substantial equivalence?
• Novelty and risk: Could a novel, lower-risk device qualify for De Novo?
• Intended use: Do the proposed indications and claims change the regulatory assessment?

High-risk software as a medical device may require PMA when it poses high clinical risk. For example, software that directs a critical clinical decision may warrant a different assessment from a lower-risk tool. The PMA process should follow the device’s actual function, claims, and risk, not its software label alone.

What is a PMA and which medical devices require FDA premarket approval?

Premarket Approval is the FDA pathway for evaluating safety and effectiveness before certain devices enter the U.S. market. Identifying the applicable pathway requires more than checking a device’s class: intended use, regulatory history, and risk also matter.

According to the Electronic Code of Federal Regulations, Title 21 CFR Part 814 governs premarket approval of medical devices. Under section 515 of the FD&C Act, Class III devices generally require a PMA application to obtain marketing approval. FDA approval must precede marketing. A Class III device that fails to meet PMA requirements is considered adulterated under section 501(f) of the Act and may not be marketed.

FDA describes Class III devices as those critical to preserving or prolonging human life, significantly helping prevent impairment of human health, or posing an unreasonable potential risk of illness or injury. That risk-based definition helps explain why the pathway calls for evidence addressing the device’s specific intended use. About 10% of devices regulated by the FDA are Class III, so classification matters, but it does not replace device-specific pathway analysis.

Consider the full regulatory profile before planning a submission:

• Classification: Identify the device class and applicable FDA classification regulation.
• Intended use: Review indications, users, and clinical purpose, since claims shape the regulatory profile.
• Regulatory history: Determine whether the device is a preamendment device marketed before the 1976 Medical Device Amendments.
• Available pathway: Evaluate whether an alternative submission type applies to the device and its predicate or risk profile.

Some Class III preamendment devices may proceed through a Class III 510(k) rather than PMA. A 510(k) demonstrates substantial equivalence to a legally marketed device; it is a clearance mechanism, not an approval process. A novel device with a lower risk profile may qualify for De Novo. These distinctions prevent treating every new technology, or every Class III designation, as an automatic PMA case.

Humanitarian Device Exemption is another distinct route. According to the U.S. Food and Drug Administration, a U.S. Humanitarian Device Exemption is intended for devices treating or diagnosing diseases or conditions affecting fewer than 8,000 people per year. HDE applications are exempt from specified effectiveness requirements, but the applicant must certify that no comparable device is available for the condition.

For a practical pathway assessment, document the device’s intended use, classification, predicate status, and regulatory history together. If the project also requires complex device assembly, discuss assembly needs for your device as its design and production plan take shape.

Fong’s Engineering & Manufacturing Private Limited: CDMO Services

Fong’s Engineering & Manufacturing Private Limited supports medical device teams that need to connect product development with controlled production. Its CDMO Services span concept design, prototyping, validation, large-scale production, and regulatory support, including FDA and ISO 13485 compliance.

Consider Fong’s CDMO Services when a device project needs coordinated development and manufacturing input. OEM Solutions support production of complete medical devices under a client’s brand, while Micro-precision Components and Complex Device Assembly address specific manufacturing needs. Endoscope Repair & Refurbishment serves a different purpose: maintaining reusable endoscopes and surgical instruments.

For a PMA-focused project, align device design, validation evidence, and production planning as the application develops. Contact Fong’s Engineering & Manufacturing Private Limited to discuss your medical device manufacturing requirements.

Put Your Device Plan Into Practice

The next step is to connect regulatory planning with decisions that shape the device itself. Use PMA medical device manufacturing requirements as a framework for aligning design intent, evidence, production records, and change control. Clear ownership across these workstreams helps keep decisions traceable as development progresses toward manufacturing.

Fong’s Engineering & Manufacturing Private Limited offers CDMO Services and OEM Solutions for medical device development and production, as well as Endoscope Repair & Refurbishment for reusable instruments. These offerings address distinct operational needs, from developing a device manufacturing plan to supporting OEM production or maintaining reusable endoscopes.

When manufacturing scope or development planning is your next priority, contact Fong’s Engineering & Manufacturing Private Limited to discuss the project. A well-aligned plan gives your team a clear basis for moving forward with discipline and confidence.

Fong’s Engineering & Manufacturing Private Limited supports medical device manufacturing

Fong’s Engineering & Manufacturing Private Limited offers end-to-end services from concept design and prototyping through validation, large-scale production, and regulatory support, including FDA and ISO 13485 compliance. For teams assessing PMA medical device manufacturing requirements, it can support development and manufacturing needs across that process.

Turn to the company when you need CDMO services, OEM solutions, micro-precision components, complex device assembly, or endoscope repair and refurbishment. It also manufactures complete medical devices under a client’s brand name using ISO 13485 certified processes.

Frequently Asked Questions

What are the key components of the FDA PMA application?

A PMA application combines administrative records with evidence supporting the device and its intended use. Core components include clinical investigation results, nonclinical testing, device descriptions, labeling, manufacturing information, and risk analyses. Applicants also address required certifications and disclosures, including Form FDA-3674 and financial information under 21 CFR 54. A useful final review checks that each conclusion in the summary points to supporting data and that referenced exhibits are included.

When is a PMA required?

A PMA is generally required when FDA classifies a device as Class III and no applicable alternative pathway applies. The classification decision depends on intended use, risk, and regulatory history, not novelty alone. For example, a lower-risk novel device may qualify for De Novo, while a device with a suitable predicate may follow 510(k). Some Class III preamendment devices may use a Class III 510(k), so check the specific device classification and submission type.

What manufacturing information must be included in an FDA PMA application?

Describe how the device is made and how production controls preserve its specifications. Manufacturing information may include production procedures, design specifications, process and sterilization validation, testing results, and controls for materials or components. For example, if the device is sterilized, connect the stated sterilization method to its validation evidence. Identify and justify any required information omitted from the application in a separate section listed in its table of contents.

What are the steps and timeline for FDA PMA review and manufacturing-site approval?

After submission, FDA first determines whether the application can be filed, then conducts substantive review and may request additional information. The U.S. Food and Drug Administration notifies applicants within 45 days whether an application has been filed; FDA has 180 days to review and decide on a PMA application. After a response to an information request, FDA may take an additional 180 days. A facility inspection is typically required before approval.

What post-approval manufacturing changes require a PMA supplement or FDA approval?

Manufacturing changes that affect the approved device or its production information may require a PMA supplement or notice before distribution. The applicable submission depends on the change and its review needs. FDA recognizes supplement types including 30-day notices and 180-day supplements. A manufacturer may distribute a device 30 days after FDA receives a 30-day notice unless FDA finds the information insufficient; FDA may convert an insufficient notice into a 135-day supplement. Review the change’s evidence and documentation before implementation.

What are FDA Quality Management System Regulation (QMSR) requirements for PMA device manufacturers?

The QMSR replaced the Quality System Regulation on February 2, 2026, and FDA quality system requirements are codified under 21 CFR Part 820. Manufacturers should maintain controls and records that support the device’s production and show that it matches the device described in the PMA.

What are PMA manufacturing requirements for contract manufacturers and foreign facilities?

Accurately represent contract manufacturers and foreign facilities in manufacturing descriptions, process records, and validation evidence. Facility inspections may review records, process controls, and validation to assess whether production controls support the device described in the PMA.